SCHEMBL2167929

SCHEMBL2167929

C=CC[C@H](CC(=O)O)O[Si](C)(C)C(C)(C)C

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ABCC4 O15439 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2167925 1.00 ABCC4 (0.31) ABCC4MAPT
SCHEMBL21464891 0.86
SCHEMBL21464893 0.86
SCHEMBL1227160 0.85 PGD (0.33)
SCHEMBL14209852 0.84 ALDH1A1 (0.39)
SCHEMBL14209800 0.84 ALDH1A1 (0.39)
SCHEMBL2636857 0.84 SMN1; SMN2 (0.35)
SCHEMBL14952637 0.84
SCHEMBL1777394 0.82
SCHEMBL2168806 0.82 DRD2 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2341054-B1 Process for the synthesis of HMG-CoA reductase inhibitors LEK PHARMACEUTICALS (SI) 2014-06-25 EP disclosed
EP-1937696-B1 PROCESS FOR THE SYNTHESIS OF HMG-CoA REDUCTASE INHIBITORS LEK PHARMACEUTICALS (SI) 2013-05-22 EP disclosed
EP-1937696-B1 PROCESS FOR THE SYNTHESIS OF HMG-CoA REDUCTASE INHIBITORS LEK PHARMACEUTICALS (SI) 2013-05-22 EP disclosed
US-8404870-B2 ((2S,4R)-4,6-dihydroxytetrahydro-2H-pyran-2-yl)methyl carboxylate and process for the production thereof LEK PHARMACEUTICALS D.D. (SI) 2013-03-26 US disclosed
US-8404870-B2 ((2S,4R)-4,6-dihydroxytetrahydro-2H-pyran-2-yl)methyl carboxylate and process for the production thereof LEK PHARMACEUTICALS D.D. (SI) 2013-03-26 US disclosed
US-8269001-B2 Process for the synthesis of HMG-CoA reductase inhibitors LEK PHARMACEUTICALS D.D. (SI) 2012-09-18 US disclosed
US-8269001-B2 Process for the synthesis of HMG-CoA reductase inhibitors LEK PHARMACEUTICALS D.D. (SI) 2012-09-18 US disclosed
EP-2341054-A1 Process for the synthesis of HMG-CoA reductase inhibitors LEK Pharmaceuticals d.d. (SI) 2011-07-06 EP disclosed
US-20110046375-A1 ((2S,4R)-4,6-DIHYDROXYTETRAHYDRO-2H-PYRAN-2-YL)METHYL CARBOXYLATE AND PROCESS FOR THE PRODUCTION THEREOF LEK PHARMACEUTICALS D.D. (SI) 2011-02-24 US disclosed
US-20080300406-A1 Process for the Synthesis of Hmg-Coa Reductase Inhibitors LEK PHARMACEUTICALS D.D. (SI) 2008-12-04 US disclosed
US-20080300406-A1 Process for the Synthesis of Hmg-Coa Reductase Inhibitors LEK PHARMACEUTICALS D.D. (SI) 2008-12-04 US disclosed
EP-1937696-A1 PROCESS FOR THE SYNTHESIS OF HMG-CoA REDUCTASE INHIBITORS LEK Pharmaceuticals D.D. (SI) 2008-07-02 EP disclosed
EP-1775299-A1 Process for the synthesis of HMG-CoA reductase inhibitors LEK Pharmaceuticals D.D. (SI) 2007-04-18 EP disclosed
WO-2007039287-A1 PROCESS FOR THE SYNTHESIS OF HMG-CoA REDUCTASE INHIBITORS LEK PHARMACEUTICALS D.D. (SI) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046375-A1 ((2S,4R)-4,6-DIHYDROXYTETRAHYDRO-2H-PYRAN-2-YL)METHYL CARBOXYLATE AND PROCESS FOR THE PRODUCTION THEREOF HMGCR, CYP4A11, CYP4B1 ABCC4 817/4885MAPT 1598/4885
US-20080300406-A1 Process for the Synthesis of Hmg-Coa Reductase Inhibitors HMGCR, COASY, LSS ABCC4 4026/4885MAPT 2143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.